Background: Respiratory syncytial virus (RSV) is the most frequent cause of lower respiratory tract infection in infants. Maternally derived RSV-specific antibodies play a role in protection against RSV infection in early life, but data regarding the concentration and specificity of those antibodies are incomplete. Methods: We prospectively enrolled a cohort of previously healthy infants and young children hospitalized (n = 45) or evaluated as outpatients (n = 20) for RSV infection, and healthy noninfected age-matched controls (n = 18). Serum samples were obtained at enrollment to quantify the concentrations and neutralizing activity of serum immunoglobulin G antibodies to the RSV prefusion (pre-F), postfusion (post-F), and G glycoproteins. We also assessed the associations between antibody concentrations and clinical disease severity. Results: Concentrations of pre-F antibodies were ≥3-fold higher than post-F antibodies and >30-fold higher than G antibodies in serum from infants with acute RSV infection. Antibody concentrations and neutralizing activity inversely correlated with age. The pre-F antibodies displayed the greatest neutralizing activity (55%-100%), followed by G (0%-45%), and post-F (0%-29%) antibodies. Higher concentrations of pre-F and G antibodies, but not post-F antibodies, were associated with lower clinical disease severity scores. Conclusions: Maternal antibodies directed to pre-F, followed by antibodies directed to G, can modulate RSV disease severity in young infants.
Background: Respiratory syncytial virus (RSV) is the most frequent cause of lower respiratory tract infection in infants. Maternally derived RSV-specific antibodies play a role in protection against RSV infection in early life, but data regarding the concentration and specificity of those antibodies are incomplete. Methods: We prospectively enrolled a cohort of previously healthy infants and young children hospitalized (n = 45) or evaluated as outpatients (n = 20) for RSV infection, and healthy noninfected age-matched controls (n = 18). Serum samples were obtained at enrollment to quantify the concentrations and neutralizing activity of serum immunoglobulin G antibodies to the RSV prefusion (pre-F), postfusion (post-F), and G glycoproteins. We also assessed the associations between antibody concentrations and clinical disease severity. Results: Concentrations of pre-F antibodies were ≥3-fold higher than post-F antibodies and >30-fold higher than G antibodies in serum from infants with acute RSV infection. Antibody concentrations and neutralizing activity inversely correlated with age. The pre-F antibodies displayed the greatest neutralizing activity (55%-100%), followed by G (0%-45%), and post-F (0%-29%) antibodies. Higher concentrations of pre-F and G antibodies, but not post-F antibodies, were associated with lower clinical disease severity scores. Conclusions: Maternal antibodies directed to pre-F, followed by antibodies directed to G, can modulate RSV disease severity in young infants.
Authors: G R O Freitas; D A O Silva; J Yokosawa; N T Paula; L F Costa; B M Carneiro; L Z G Ribeiro; T F M Oliveira; J R Mineo; D A O Queiróz Journal: J Med Virol Date: 2011-10 Impact factor: 2.327
Authors: Helen Y Chu; Mark C Steinhoff; Amalia Magaret; Khalequ Zaman; Eliza Roy; Gretchen Langdon; Mary Anne Formica; Edward E Walsh; Janet A Englund Journal: J Infect Dis Date: 2014-06-05 Impact factor: 5.226
Authors: Sandra Fuentes; Roberta L Crim; Judy Beeler; Michael N Teng; Hana Golding; Surender Khurana Journal: Vaccine Date: 2013-06-04 Impact factor: 3.641
Authors: Supranee Chaiwatpongsakorn; Raquel F Epand; Peter L Collins; Richard M Epand; Mark E Peeples Journal: J Virol Date: 2011-02-09 Impact factor: 5.103
Authors: Margarita Magro; Vicente Mas; Keith Chappell; Mónica Vázquez; Olga Cano; Daniel Luque; María C Terrón; José A Melero; Concepción Palomo Journal: Proc Natl Acad Sci U S A Date: 2012-02-08 Impact factor: 11.205
Authors: Jason S McLellan; Man Chen; Sherman Leung; Kevin W Graepel; Xiulian Du; Yongping Yang; Tongqing Zhou; Ulrich Baxa; Etsuko Yasuda; Tim Beaumont; Azad Kumar; Kayvon Modjarrad; Zizheng Zheng; Min Zhao; Ningshao Xia; Peter D Kwong; Barney S Graham Journal: Science Date: 2013-04-25 Impact factor: 47.728
Authors: Asuncion Mejias; Blerta Dimo; Nicolas M Suarez; Carla Garcia; M Carmen Suarez-Arrabal; Tuomas Jartti; Derek Blankenship; Alejandro Jordan-Villegas; Monica I Ardura; Zhaohui Xu; Jacques Banchereau; Damien Chaussabel; Octavio Ramilo Journal: PLoS Med Date: 2013-11-12 Impact factor: 11.069
Authors: Stanislav O Fedechkin; Natasha L George; Ana M Nuñez Castrejon; Joshua R Dillen; Lawrence M Kauvar; Rebecca M DuBois Journal: J Virol Date: 2020-02-28 Impact factor: 5.103
Authors: Bo Liang; Barbora Kabatova; Juraj Kabat; David W Dorward; Xiang Liu; Sonja Surman; Xueqiao Liu; Annie Park Moseman; Ursula J Buchholz; Peter L Collins; Shirin Munir Journal: J Virol Date: 2019-03-21 Impact factor: 5.103
Authors: Edward E Walsh; Lu Wang; Ann R Falsey; Xing Qiu; Anthony Corbett; Jeanne Holden-Wiltse; Thomas J Mariani; David J Topham; Mary T Caserta Journal: J Infect Dis Date: 2018-06-20 Impact factor: 5.226
Authors: Jorge C G Blanco; Marina S Boukhvalova; Trudy G Morrison; Stefanie N Vogel Journal: Hum Vaccin Immunother Date: 2018-06-19 Impact factor: 3.452